The –ibs, –abs and Beyond—Immunotherapies for Pediatric Cancer Treatment and What They Mean for Pain and Symptom Management and Patient Prognosis (TH337)

Use of Immunotherapy for pediatric cancer treatment is rapidly increasing. Medications such as blinatumomab, dinutuxumab, tisagenleclucel and others are dramatically changing the field of pediatric Oncology, and it is imperative that Pediatric Palliative Care (PPC) providers understand pain and symptom management needs as well as changes in prognosis for patients undergoing intensive immunotherapy.
Source: Journal of Pain and Symptom Management - Category: Palliative Care Authors: Source Type: research